| アブストラクト | PURPOSE: This study aimed to assess the drug risk of drug-related keratitis and track the epidemiological characteristics of drug-related keratitis. METHODS: This study analyzed data from the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database from January 2004 to December 2023. A disproportionality analysis was conducted to assess drug-related keratitis with positive signals, and drugs were classified and assessed with regard to their drug-induced timing and risk of drug-related keratitis. RESULTS: A total of 1606 drugs were reported to pose a risk of drug-related keratitis in the FAERS database, and, after disproportionality analysis and screening, 17 drugs were found to significantly increase the risk of drug-related keratitis. Among them, seven were ophthalmic medications, including dorzolamide (reporting odds ratio [ROR] = 3695.82), travoprost (ROR = 2287.27), and brimonidine (ROR = 2118.52), and 10 were non-ophthalmic medications, including tralokinumab (ROR = 2609.12), trazodone (ROR = 2377.07), and belantamab mafodotin (ROR = 680.28). The top three drugs having the highest risk of drug-related keratitis were dorzolamide (Bayesian confidence propagation neural network [BCPNN] = 11.71), trazodone (BCPNN = 11.11), and tralokinumab (BCPNN = 11.08). The drug-induced times for non-ophthalmic medications were significantly shorter than those for ophthalmic medications (mean days, 141.02 vs. 321.96, respectively; P < 0.001). The incidence of drug-related keratitis reached its peak in 2023. CONCLUSIONS: Prevention of drug-related keratitis is more important than treatment. Identifying the specific risks and timing of drug-induced keratitis can support the development of preventive measures. TRANSLATIONAL RELEVANCE: Identifying the specific drugs related to medication-related keratitis is of significant importance for drug vigilance in the occurrence of drug-related keratitis. |
|---|
| ジャーナル名 | Translational vision science & technology |
|---|
| Pubmed追加日 | 2024/9/17 |
|---|
| 投稿者 | Wu, Shi-Nan; Chen, Xiao-Dong; Zhang, Qing-He; Wang, Yu-Qian; Yan, Dan; Xu, Chang-Sheng; Wang, Shao-Pan; Zhu, Linfangzi; Qin, Dan-Yi; Guo, Shu-Jia; Chen, Lin; Liu, Yu-Wen; Huang, Caihong; Hu, Jiaoyue; Liu, Zuguo |
|---|
| 組織名 | Xiamen University Affiliated Xiamen Eye Center, Fujian Provincial Key Laboratory;of Ophthalmology and Visual Science, Fujian Engineering and Research Center of;Eye Regenerative Medicine, Eye Institute of Xiamen University, School of;Medicine, Xiamen University, Xiamen, Fujian, China.;Department of Ophthalmology, The First Affiliated Hospital of University of South;China, Hengyang, Hunan, China.;Institute of Artificial Intelligence, Xiamen University, Xiamen, Fujian, China.;Department of Ophthalmology, Xiang'an Hospital of Xiamen University, Xiamen,;Fujian, China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39287587/ |
|---|
